×
About 76,055 results

ALLMedicine™ Multiple Sclerosis Center

Research & Reviews  23,428 results

Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of c...
https://doi.org/10.1177/13524585221094239
Multiple Sclerosis (Houndmills, Basingstoke, England); Ford CC, Cohen JA et. al.

Jul 1st, 2022 - Glatiramer acetate (GA) is US-approved for relapsing multiple sclerosis. To describe GA long-term clinical profile. To compare effectiveness of early start (ES) versus delayed start (DS; up to 3 years) with GA. Phase 3 trial participants entered a...

The effectiveness of aromatherapy and reflexology in neurodegenerative disorders: a sys...
https://doi.org/10.2217/nmt-2021-0056
Neurodegenerative Disease Management; Rawal R, Armstrong M et. al.

Jul 1st, 2022 - Many neurodegenerative conditions are chronic disorders and result in a range of debilitating symptoms, with many people turning to complementary therapies. A systematic review and meta-analysis were conducted to investigate the evidence on effect...

Disease-Modifying Therapies in Progressive Multiple Sclerosis
https://www.mdedge.com/neurology/article/255818/multiple-sclerosis/disease-modifying-therapies-progressive-multiple
Robert Shin, MD

Jun 30th, 2022 - Dr Robert Shin, from Georgetown University Hospital, highlights key presentations in disease-modifying therapy for multiple sclerosis (MS) presented at the 2022 annual meeting of the Consortium of Multiple Sclerosis Centers. First, Dr Shin discuss.

Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in mu...
https://doi.org/10.1177/13524585221104014
Multiple Sclerosis (Houndmills, Basingstoke, England); Marastoni D, Crescenzo F et. al.

Jun 30th, 2022 - Data on the effect of dimethyl fumarate (DMF) on focal and diffuse gray matter (GM) damage, a relevant pathological substrate of multiple sclerosis (MS)-related disability are lacking. To evaluate the DMF effect on cortical lesions (CLs) accumulat...

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 year...
https://doi.org/10.1177/13524585221102584
Multiple Sclerosis (Houndmills, Basingstoke, England); Cree BA, Selmaj KW et. al.

Jun 30th, 2022 - Ozanimod, an oral sphingosine 1-phosphate receptor 1 and 5 modulator, is approved in multiple countries for treatment of relapsing forms of MS. To characterize long-term safety and efficacy of ozanimod. Patients with relapsing MS who completed a p...

see more →

Guidelines  16 results

Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinic...
https://doi.org/10.1016/j.apmr.2022.05.010
Archives of Physical Medicine and Rehabilitation; Rider JV, Selim J

Jun 18th, 2022 - Supporting the Role of Parenting for People with Multiple Sclerosis: A Guide for Clinicians.|2022|Rider JV,Selim J,|

Vision Problems in Multiple Sclerosis.
https://doi.org/10.1016/j.apmr.2020.08.003
Archives of Physical Medicine and Rehabilitation; Costa SL, Pandey K et. al.

Sep 29th, 2020 - Vision Problems in Multiple Sclerosis.|2020|Costa SL,Pandey K,Hrdina J,Rondon M,Devos H,|

Serum neurofilament light as a biomarker in progressive multiple sclerosis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7538221
Neurology Kapoor R, Smith KE et. al.

Jul 18th, 2020 - There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes...

Practical Sleep Information for People With Multiple Sclerosis.
https://doi.org/10.1016/j.apmr.2020.03.009
Archives of Physical Medicine and Rehabilitation; Siengsukon C, Karahan AY et. al.

May 14th, 2020 - Practical Sleep Information for People With Multiple Sclerosis.|2020|Siengsukon C,Karahan AY,Strober L,|

Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis...
https://doi.org/10.1016/j.msard.2019.04.004
Multiple Sclerosis and Related Disorders; Lebrun C, Vukusic S et. al.

Jun 5th, 2019 - To establish recommendations on immunization for patients with multiple sclerosis (MS) BACKGROUND: Vaccines have been suspected in the past to trigger MS and relapses. With the extension of the immunoactive treatment arsenal, other concerns have b...

see more →

Drugs  390 results see all →

Clinicaltrials.gov  2,551 results

Uveitis/Intraocular Inflammatory Disease Biobank (iBank)
https://clinicaltrials.gov/ct2/show/NCT02656381

Jun 24th, 2022 - Uveitis refers to a large group of intraocular inflammatory diseases that can cause devastating visual loss in adults and children. This study establishes a clinical database and biospecimen repository for the identification of novel factors relev...

Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
https://clinicaltrials.gov/ct2/show/NCT01617395

Jun 24th, 2022 - Objective. The overall objective of this study is to investigate the genetic, immune, and neuroimaging profiles that may increase a person s risk of developing multiple sclerosis (MS) in order to identify and validate predictive biomarkers in popu...

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
https://clinicaltrials.gov/ct2/show/NCT02784210

Jun 24th, 2022 - Objectives. The primary aim of this pilot study is to assess the effects of short-term, high-dose corticosteroid administration on the 12-week evolution of multiple sclerosis lesions with centripetal enhancement pattern on magnetic resonance imagi...

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
https://clinicaltrials.gov/ct2/show/NCT04799288

Jun 24th, 2022 - Study Description: In this single center, single arm, open label, baseline versus treatment pilot clinical trial, sixteen subjects with HAM/TSP will receive teriflunomide 14mg by mouth once a day in an initial 9 month treatment phase, followed by ...

A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
https://clinicaltrials.gov/ct2/show/NCT02634307

Jun 24th, 2022 - The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over ti...

see more →

News  3,980 results

Disease-Modifying Therapies in Progressive Multiple Sclerosis
https://www.mdedge.com/neurology/article/255818/multiple-sclerosis/disease-modifying-therapies-progressive-multiple
Robert Shin, MD

Jun 30th, 2022 - Dr Robert Shin, from Georgetown University Hospital, highlights key presentations in disease-modifying therapy for multiple sclerosis (MS) presented at the 2022 annual meeting of the Consortium of Multiple Sclerosis Centers. First, Dr Shin discuss.

Fast Five Quiz: Relapsing-Remitting Multiple Sclerosis Management
https://www.medscape.com/viewarticle/936615

Jun 30th, 2022 - Relapsing-remitting multiple sclerosis (RRMS) accounts for approximately 85% of multiple sclerosis (MS) cases. It is characterized by recurrent episodes of various neurologic deficits that resolve over a short period with variable to no obvious re...

Fast Five Quiz: Treatment In Relapsed Multiple Sclerosis
https://www.medscape.com/viewarticle/974624

Jun 30th, 2022 - Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system and often causes significant physical disability over time. The hallmark of MS is symptomatic episodes "separated in tim...

Fast Five Quiz: Key Aspects of Multiple Sclerosis Treatment
https://www.medscape.com/viewarticle/900948

Jun 30th, 2022 - Multiple sclerosis (MS), an immune-mediated inflammatory disease, attacks myelinated axons in the central nervous system. In people with MS, rates and degrees of disability vary widely and are related to the location and amount of axonal damage, s...

Autoimmune disorder drugs top list of meds linked to headache
https://www.mdedge.com/neurology/article/255727/headache-migraine/autoimmune-disorder-drugs-top-list-meds-linked-headache
Randy Dotinga

Jun 23rd, 2022 - DENVER – Monoclonal antibodies, antivirals, immunomodulators, and pulmonary arterial vasodilators top the list of drugs that were most frequently implicated as causes of headaches in a federal side effect database that anyone can contribute to, ac.

see more →

Patient Education  57 results see all →